The FDA has revised a nearly 20-year-old final guidance document on user fees applicable to combination products in light of the agency’s current user fee programs and its current guidance on the user fees charged for drug, biological product and medical device submissions. The revised guidance — “Application User Fees for Combination Products” — addresses user fees assessed ... Read More